These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25342601)

  • 1. Epidermal growth factor receptor and variant III targeted immunotherapy.
    Congdon KL; Gedeon PC; Suryadevara CM; Caruso HG; Cooper LJ; Heimberger AB; Sampson JH
    Neuro Oncol; 2014 Oct; 16 Suppl 8(Suppl 8):viii20-5. PubMed ID: 25342601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.
    Wikstrand CJ; Reist CJ; Archer GE; Zalutsky MR; Bigner DD
    J Neurovirol; 1998 Apr; 4(2):148-58. PubMed ID: 9584952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor antigens in astrocytic gliomas.
    Kurpad SN; Zhao XG; Wikstrand CJ; Batra SK; McLendon RE; Bigner DD
    Glia; 1995 Nov; 15(3):244-56. PubMed ID: 8586461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma.
    Sonabend AM; Dana K; Lesniak MS
    Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S45-50. PubMed ID: 18076318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for glioma: getting closer to the clinical arena?
    Finocchiaro G; Pellegatta S
    Curr Opin Neurol; 2011 Dec; 24(6):641-7. PubMed ID: 22027543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Passive antibody-mediated immunotherapy for the treatment of malignant gliomas.
    Mitra S; Li G; Harsh GR
    Neurosurg Clin N Am; 2010 Jan; 21(1):67-76. PubMed ID: 19944967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel immunotherapeutic approach].
    Kikuchi T
    Gan To Kagaku Ryoho; 2005 Apr; 32(4):453-7. PubMed ID: 15853209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of human glioma xenografts with unlabeled, 131I-, or 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor.
    Bender H; Takahashi H; Adachi K; Belser P; Liang SH; Prewett M; Schrappe M; Sutter A; Rodeck U; Herlyn D
    Cancer Res; 1992 Jan; 52(1):121-6. PubMed ID: 1727372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel mechanisms and approaches in immunotherapy for brain tumors.
    Finocchiaro G; Pellegatta S
    Discov Med; 2015; 20(108):7-15. PubMed ID: 26321082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell- and peptide-based immunotherapeutic approaches for glioma.
    Yamanaka R
    Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor immunology: a neurosurgical perspective. II. The immunology of glial neoplasms.
    Apuzzo ML
    Bull Los Angeles Neurol Soc; 1976 Oct; 41(4):176-83. PubMed ID: 74264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glioma immunology and immunotherapy.
    Parney IF; Hao C; Petruk KC
    Neurosurgery; 2000 Apr; 46(4):778-91; discussion 791-2. PubMed ID: 10764250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGF receptor variant III as a target antigen for tumor immunotherapy.
    Li G; Wong AJ
    Expert Rev Vaccines; 2008 Sep; 7(7):977-85. PubMed ID: 18767947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel immunotherapeutic approaches to glioma.
    Yamanaka R
    Curr Opin Mol Ther; 2006 Feb; 8(1):46-51. PubMed ID: 16506525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients].
    Kubo O; Takakura K
    Nihon Rinsho; 2002 Mar; 60(3):497-503. PubMed ID: 11904965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization.
    Johns TG; Perera RM; Vernes SC; Vitali AA; Cao DX; Cavenee WK; Scott AM; Furnari FB
    Clin Cancer Res; 2007 Mar; 13(6):1911-25. PubMed ID: 17363548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin-1 and immunotherapy for brain cancer.
    Verschuere T; De Vleeschouwer S; Lefranc F; Kiss R; Van Gool SW
    Expert Rev Neurother; 2011 Apr; 11(4):533-43. PubMed ID: 21469926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo.
    Arwert E; Hingtgen S; Figueiredo JL; Bergquist H; Mahmood U; Weissleder R; Shah K
    Cancer Res; 2007 Aug; 67(15):7335-42. PubMed ID: 17671203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
    Prins RM; Odesa SK; Liau LM
    Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Peptide vaccination therapy for malignant glioma].
    Yamanaka R; Itoh K
    Brain Nerve; 2007 Mar; 59(3):251-61. PubMed ID: 17370651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.